The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations

<table class="table-group" id="tab5"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td class="align_left">—</td><td class="align_center">Cardinality</td><td class="align_center">Degrees of freedom</td><td class="align_center">Significance</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td class="align_left">Log rank (Mantel-Cox)</td><td class="align_center">6.791</td><td class="align_center">2</td><td class="align_center">0.034</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>Equivalence tests of survival analysis distributions were performed for different levels of experimental subgroups.<br/></div></td></tr></table>

Contrast Media & Molecular Imaging

tab5

Table 5

Table 5: The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations 